The FDA Tracker is a page on Amino Axiom, a free research information platform that also hosts a compound library, a vendor directory, price comparison, a compare tool, a glossary and keyword search. The tracker records the regulatory status of research compounds, so a reader can see how each one is currently treated by the agency. It lives at the FDA Tracker.
It is an information page. It reports status; it does not interpret what a status means for any laboratory's obligations, and it is not legal or regulatory advice. A researcher who needs a definitive answer for a specific project still has to consult primary agency documents and the institution's compliance office.
Why does regulatory status matter to an incretin research program?
Incretin-class compounds sit in an unusual position. Some molecules in the class have been through formal agency review in other contexts, while others exist only as research tools described in the preclinical literature. Both kinds can appear in the same catalog, and a study that compares them is working across that boundary.
For a laboratory, the status of a compound affects planning in several ways that have nothing to do with its pharmacology. It can bear on how a supplier is allowed to describe a product, on what documentation an institution expects before purchase, and on how a manuscript should characterize the material. Knowing where a compound stands at the start of a project avoids surprises late in the process.
What does the tracker show?
The page is organized by compound. For each entry a reader can expect a name and a status category, along with a short description of the regulatory position and the date of the most recent change. Entries can be scanned as a list or opened individually.
The tracker records status, not quality. Two compounds can share a status and differ widely in how well characterized they are in the literature. Equally, a compound with a status that sounds restrictive may have a large body of published preclinical work. The page reports the first fact and leaves the second to the literature.
Because regulatory positions change, the date on each entry matters as much as the status itself. As of October 2026, the entries a lab reads today may differ from those read earlier in the year. A researcher using the page for planning should record the date viewed along with the status read, so later readers of the project notes know how current the information was.
How would an incretin lab read an entry?
Suppose a group is planning a comparison across three scaffolds in a receptor signaling assay: native GLP-1, the lipidated analog GLP-1(S) and the multi-receptor scaffold GLP-3(R). A practical sequence for using the tracker looks like this:
Find each compound on the tracker and note its status category.
Record the date of the latest change and the date the page was viewed.
Read the short description of the regulatory position and note any wording that differs between entries.
Compare the three results. If they differ, ask whether the difference affects documentation, purchasing or reporting for the study.
Confirm anything that matters for the project against primary sources, and keep the citation in the project notes.
None of these steps involves any claim about what the compounds do. They are administrative steps that sit alongside the science and that a lab can complete before any material is ordered.
How does status relate to the identity of the material?
A regulatory entry refers to a named compound, and a laboratory still has to confirm that the material it holds is that compound. The catalog identifiers are the starting point. Native GLP-1 is listed here at 3337.73 g/mol with a formula of C151H226N40O46 and CAS 106612-94-6 (GLP-1 7-37). GLP-1(S) is listed at 4113.58 g/mol with C187H291N45O59 and CAS 910463-68-2. GLP-3(R) is listed at 4731.33 g/mol with C221H342N46O68 and CAS 2381089-83-2.
An intact mass measurement by liquid chromatography and mass spectrometry that matches the listed value within instrument tolerance supports identity. That check is independent of any status entry, and it is what ties a regulatory record to a physical sample. Where a status entry names a compound loosely, for instance by a family name, the formula and mass in the catalog help the researcher see exactly which molecule is meant.
What should a lab record from the tracker?
Good practice is to treat a tracker reading like any other source in a methods record. A short note per compound is enough:
The compound name as used in the lab, and the identifiers held for it.
The status category and description as read.
The date the page was viewed and the date of the latest change shown.
Any follow-up taken, such as an inquiry to the institution's compliance office.
This takes a few minutes per compound and gives a reviewer a clear trail. If a status changes midway through a long study, the record shows what the lab knew at the start and when it learned of the change.
What are the limits of a status tracker?
Three limits are worth stating plainly.
First, it is a summary of public information and can lag behind events. A reader should treat it as a pointer to primary sources rather than as the source itself.
Second, status is not a statement about science. A compound's regulatory category says nothing about its receptor selectivity, its stability or the strength of the evidence for any research finding. Those questions belong to the published pharmacology and the lab's own assays.
Third, the page cannot reflect the policies of any particular institution. A university or company may apply rules that go beyond what is shown, and the lab must follow those regardless of what the tracker lists.
Where does the tracker fit in a research workflow?
The tracker belongs at the planning stage, with the other desk-based checks a lab does before purchasing: reviewing the literature, confirming identifiers, and qualifying a supplier. It also earns a second look at the writing stage, when the manuscript's description of each material should match what is publicly recorded.
For incretin programs, where a single project may span reference peptides and newer multi-receptor scaffolds, a short table with one row per compound and columns for identifiers, status and date read is often all that is needed. The tracker supplies the status column, the catalog supplies the identifiers, and the lab's own analytical work supplies confirmation.
The platform's homepage at Amino Axiom lists the other surfaces it offers. For this article the relevant one is the tracker, and the walkthrough above is intended to show how its entries can be read as planning context for incretin research.
Research use disclaimer
All compounds referenced in this article are supplied for laboratory research use only. They are not intended for human or veterinary use, and nothing here describes or implies any use outside in vitro and other controlled research settings. Descriptions of Amino Axiom reflect only what its FDA Tracker page visibly presents. For research purposes only.
Reference
Common questions
The FDA Tracker records the regulatory status of research compounds. Each entry gives a compound name, a status category, a short description of the regulatory position and the date of the most recent change. It reports status only and is not legal or regulatory advice; primary agency documents remain the authority.
A lab should record the compound name and identifiers, the status category and description as read, the date the page was viewed, and the date of the latest change shown. Any follow-up, such as a question to the compliance office, should be noted too. Dating the reading shows what was known at the start of a study.
No. A status category says nothing about receptor selectivity, stability or the strength of evidence for any research finding. Two compounds can share a status and differ widely in how well characterized they are. Those questions belong to published pharmacology and the laboratory's own assays.
No. The tracker names compounds, but identity must be confirmed on the material itself, for example by intact mass spectrometry matching the catalog value within instrument tolerance. In the catalog, native GLP-1 is 3337.73 g/mol and GLP-3(R) is 4731.33 g/mol, which helps tie a regulatory entry to the right molecule.
